Trethera, founded with a mission to revolutionize cancer treatment, focuses on developing small molecule therapies that precisely target nucleotide metabolism to control DNA replication and integrity. The company's innovative approach aims to overcome the limitations of single-agent treatments and mitigate the risks of treatment failure and drug resistance. Trethera's combination therapies address alternative pathways of nucleotide biosynthesis, specifically the de novo and salvage pathways, as well as mechanisms that protect cancer genomes against DNA replication stress. Their market focus includes treatments for cancers and autoimmune diseases.

Notable affiliated individuals include experienced scientists and industry leaders who have significantly contributed to the field of biotechnology. Trethera has garnered attention from prominent investors in the biotech sector, aiding in its research and development efforts. Key achievements include advancing their proprietary therapies through preclinical stages, demonstrating efficacy in targeting cancer cells, and progressing towards clinical trials. Trethera's impact lies in its potential to offer more effective and resilient treatment options for patients battling cancer and autoimmune diseases.